MedTrace Logo

A Real-World Study of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer

NCT04822103 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 155

Last updated 2022-03-18

No results posted yet for this study

Summary

The role of preoperative chemotherapy as standard therapy is well-established for advanced esophageal cancer. Immunotherapeutic agents such as Immune checkpoint inhibitors has been shown to improve objective response rate in solid tumors. However, there is a paucity of data regarding the efficacy and safety of preoperative immunotherapy plus chemotherapy in esophageal cancer patients in real-world practice. This study set out to investigate whether the combination of preoperative chemotherapy and immune checkpoint inhibitors is beneficial to improve the objective response rate as well as the pathological complete response rate in a real-world scenario.

Conditions

  • Esophageal Cancer

Sponsors & Collaborators

  • The People's Hospital of Gaozhou

    collaborator OTHER

  • The General Hospital of Southern Theater Command

    collaborator OTHER

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    collaborator OTHER

  • First Affiliated Hospital of Shantou University Medical College

    collaborator OTHER

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Shantou Central Hospital

    collaborator OTHER

  • Shenzhen People's Hospital

    collaborator OTHER

  • Guangdong Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Guibin Qiao, MD · Guangdong Provincial People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-10-01
Completion
2021-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04822103 on ClinicalTrials.gov